Email
: Dan Granoff
Phone: 510-450-7640

CHORI Staff Directory
CHORI Intranet
CHORI News

PEER REVIEWED RESEARCH ARTICLES, 2011-2013

2013
Lewis LA, Vu DM, Vasudhev S, Shaughnessy J, Granoff DM, and Ram S. Factor H-dependent alternative pathway inhibition mediated by porin B contributes to virulence of Neisseria meningitidis. mBio, 2013; 4:e00339-e00413. PubMed ID: 24129254.
PDF

Rossi R, Granoff DM, and Beernink PT. Meningococcal factor H-binding protein vaccines with decreased binding to human complement factor H have enhanced immunogenicity in human factor H transgenic mice. Vaccine, 2013; 31:5451-7. PubMed ID: 24035433.
Abstract


Konar M, Granoff DM, Beernink PT. Importance of inhibition of binding of complement factor H for serum bactericidal antibody responses to meningococcal factor H-binding protein vaccines. Journal of Infectious Diseases, 2013; June 26, Epub. PubMed ID: 23715659.
Abstract

Pajon R, Fergus AM, and Granoff DM. Mutant native outer membrane vesicles combined with a serogroup A polysaccharide conjugate vaccine for prevention of meningococcal epidemics in Africa. PLoS One, 2013; 8:e66536. PubMed ID: 23805230.
PDF

Giuntini S, Vu DM, and Granoff DM. fH-dependent complement evasion by disease-causing meningococcal strains with absent fHbp genes or frameshift mutations. Vaccine, 2013; June 17, Epub. PubMed ID: 23791680.
Abstract

Granoff DM, Ram S, and Beernink PT. Does binding of complement factor H to the meningococcal vaccine antigen, factor H-binding protein, decrease protective serum antibody responses? Clinical and Vaccine Immunology, 2013; June 5, Epub. PubMed ID: 23740919.
PDF

Granoff DM. Portrait: Coincidences, convergences and opportunities. Human Vaccines and Immunotherapeutics, 2013; 9:945-49. PubMed ID: 23807081.
PDF

Granoff DM. Commentary: European Medicines Agency recommends approval of a broadly protective vaccine against serogroup B meningococcal disease. Pediatric Infectious Disease Journal, 2013; 32:372-73. PubMed ID: 23263177.
Citation

2012
Pajon R, Beernink PT, and Granoff DM. Design of meningococcal factor H binding protein mutant vaccines that do not bind human complement factor H. Infection and Immunity, 2012; 80:2667-677. PubMed ID: 22615247.
PDF

Beernink PT, Shaughnessy J, Pajon R, Braga EM, Ram S, and Granoff DM. The effect of human factor H on immunogenicity of meningococcal native outer membrane vesicle vaccines with over-expressed factor H binding protein. PLoS Pathogens, 2012; 8:e1002688. PubMed ID: 22589720.
PDF

Vu DM, Pajon R, Reason DC, and Granoff DM. A broadly cross-reactive monoclonal antibody against an epitope on the N-terminus of meningococcal fHbp. Scientific Reports, 2012; 2:341. PubMed ID: 22461972.
PDF

Giuntini S, Beernink PT, Reason DC, and Granoff DM. Monoclonal antibodies to meningococcal factor H binding protein with overlapping epitopes and discordant functional activity.  PLoS One, 2012; 7:e34272. PubMed ID: 22461909.
PDF

Vu DM, Shaughnessy J, Lewis LA, Ram S, Rice PA, and Granoff DM.  Enhanced bacteremia in human factor H transgenic rats infected by Neisseria meningitidis. Infection and Immunity, 2012; 80:643-50. PubMed ID: 22104107.
PDF

Giuntini S, Reason DC, and Granoff DM. Combined roles of human IgG subclass, alternative complement pathway activation, and epitope density on bactericidal activity of antibodies to meningococcal factor H binding protein. Infection and Immunity, 2012; 80:187-94.  PubMed ID: 22064712.
PDF

2011
Pajon R, Fergus AM, Koeberling O, Caugant DA, and Granoff DM. Meningococcal factor H binding proteins in epidemic strains from Africa: implications for vaccine development. PLoS Neglected Tropical Diseases, 2011; 5:e1302. PubMed ID: 21909444.
PDF

Giuntini S, Reason DC, and Granoff DM. Complement-mediated bactericidal activity of anti-factor H binding protein monoclonal antibodies against the meningococcus relies upon blocking factor H binding. Infection and Immunity, 2011; 79:3751-59. PubMed ID: 21708990.
PDF

Koeberling O, Seubert A, Santos G, Colaprico A, Ugozzoli M, Donnelly D, and Granoff DM. Immunogenicity of a meningococcal native outer membrane vesicle vaccine with attenuated endotoxin and over-expressed factor H binding protein in infant rhesus monkeys. Vaccine, 2011; 29:4728-34.  PubMed ID: 21571025.
Abstract

Koeberling O, Delaney I, and Granoff DM.  A critical threshold of meningococcal factor H binding protein is required for increased breadth of protective antibodies elicited by native outer membrane vesicle vaccines. Clinical and Vaccine Immunology, 2011; 18:736-42. PubMed ID: 21367981.
PDF

Beernink PT, Shaughnessy J, Braga EM, Liu Q, Rice PR, Ram S, and Granoff DM. A meningococcal factor H binding protein mutant that eliminates factor H binding enhances protective antibody responses to vaccination. Journal of Immunology, 2011; 186:3606-14. PubMed ID: 21325619.
PDF

Vu DM, Wong TT, and Granoff DM. Cooperative serum bactericidal activity between human antibodies to meningococcal factor H binding protein and Neisserial heparin binding antigen. Vaccine, 2011; 29:1968-1973. PubMed ID: 21241734.
PDF

Dunphy KY, Beernink PT, Brogioni B, and Granoff DM. Effect of factor H-binding protein sequence variation on factor H binding and survival of Neisseria meningitidis in human blood. Infection and Immunity, 2011; 79:353-359. PubMed ID: 21041484.
PDF

CHAPTERS
Granoff DM, Pelton S, and Harrison LH. Meningococcal vaccines. In: Plotkin SA, Orenstein WA, and Offit PA, editors. Vaccines. 6th ed. Philadelphia: Saunders Elsevier; 2013. p 388-418.

Granoff DM and Gilsdorf JR. Neisseria meningitidis (Meningococcus). In:  Kliegman RM, Stanton B, St. Geme J, Schor N, and Behrman RE, editors. Nelson Textbook of Pediatrics. 19th ed. Philadelphia: Saunders Elsevier; 2011. p 929-935.

Revised: Friday, November 14, 2014 2:07 PM

 


© 2005 Children's Hospital Oakland Research Institute
5700 Martin Luther King Jr Way • Oakland, California 94609
Phone 510-450-7600 • Fax 510-450-7910
Site MapDisclaimer

granoff_web_pubs.doc